The characterisation of specific MyD88 pathways driving cancer- and chemotherapy-induced cognitive dysfunction will be important, and may point to additional genetic polymorphisms or biomarkers of these pathways useful for identifying patients at high risk of cognitive dysfunction. The gene discussed is MYD88; the disease is cancer.